Sylvain Cottens

This inventor holds 15 USPTO granted patents and 12 published patent applications and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Novartis Ag, Sandoz Gmbh, Other. Active years: 1992-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sylvain Cottens. Retrieved from https://idiyas.com/inventor/sylvain-cottens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 12)

% Patents Active = 66.7

EPO Patents = 1 (Patent Applications = 10)

Average Co-Inventor Count = 2.9

ph-index = 7

Forward Citations = 393(Granted Patents)

Location History:

Witterswil, CH (1992 - 2010)
Witterswil 4108, CH (2010)

Company Filing History:

2 out of 834,601

Other

patents

Years Active: 1992-2010

Loading Chart...

Areas of Expertise:

Indolylmaleimide Derivatives

Pharmaceutical Compositions

Rapamycin Derivatives

Lymphocyte Function Antigen-1 Antagonists

Immunosuppressants

2-Amino-Propanol Derivatives

Melvinolin Derivatives

O-Alkylated Rapamycin Derivatives

1,3-Propanediol Derivatives

Halogenoalkylphenyl-Alcohols

Ketones

Hydrates

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7825124 - Indolylmaleimide derivatives (2010-11-02),

2. 7786123 - Indolylmaleimide derivatives (2010-08-31),

3. 7326801 - 2-amino-propanol derivatives (2008-02-05),

4. 7205279 - Pharmaceutical compositions (2007-04-17),

5. 6818638 - Melvinolin derivatives (2004-11-16),

6. 6645970 - Indolylmaleimide derivatives (2003-11-11),

7. 6630492 - Lymphocyte function antigen-1 antagonists (2003-10-07),

8. 6486209 - Use for 1,3-propanediol derivatives (2002-11-26),

9. 6440990 - O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants (2002-08-27),

10. 6274629 - Use for 1,3-propanediol derivatives (2001-08-14),

11. 6200985 - Rapamycin derivatives (2001-03-13),

12. 5985890 - Rapamycin derivatives (1999-11-16),

13. 5912253 - Rapamycin derivatives (1999-06-15),

14. 5665772 - O-alkylated rapamycin derivatives and their use, particularly as (1997-09-09),

15. 5166181 - Halogenoalkylphenyl-alcohols, ketones and hydrates thereof (1992-11-24),

Title: Sylvain Cottens: A Pioneer of Innovation in the World of Pharmaceuticals

Introduction: Sylvain Cottens, a renowned inventor hailing from Witterswil, CH, stands as a testament to the power of innovation and perseverance in the realm of inventing. With a remarkable portfolio of 15 patents and a dedication to pushing technological boundaries, his work continues to inspire inventors and researchers globally.

Latest Patents: Among his latest patents are the groundbreaking inventions of Indolylmaleimide derivatives. These derivatives, comprising various residues like substituted phenyl, naphthyl, and pyrimidinyl, showcase significant pharmaceutical properties. They have shown promise in treating and preventing T-cell mediated acute or chronic inflammatory diseases, autoimmune conditions, graft rejections, and even cancer.

Career Highlights: Sylvain Cottens has made significant contributions in the pharmaceutical industry through his work with esteemed companies like Novartis AG and Sandoz GmbH. His innovative mindset and relentless pursuit of scientific advancements have shaped the landscape of pharmaceutical research.

Collaborations: Throughout his career, Cottens has collaborated with esteemed professionals in the field, including Richard Sedrani and Rainer Albert. These partnerships have led to the development of cutting-edge solutions and novel approaches in addressing various medical challenges.

Conclusion: In conclusion, Sylvain Cottens' journey as an inventor exemplifies the impact of determination and ingenuity in driving progress within the realm of pharmaceutical innovation. His work not only reflects a commitment to excellence but also serves as a source of inspiration for future generations of inventors and researchers worldwide.

Profile summary based on public USPTO records.